Massachusetts mobilizes against device tax; Next-gen stents appear safer;

@FierceMedDev: Medtronic will pay $85M to resolve Infuse shareholder suit. Item | Follow @FierceMedDev

> Massachusetts medical device companies and lobbyists are mobilizing against the 2.3% tax on device sales, passed as part of the health reform law that's scheduled to debut next year. Story

> New long-term data compiled from a number of trials suggests that second-generation stents, including those made with a biodegradable polymer, reduce the likelihood of blood clots and target lesion revascularization compared with first-generation drug-eluting stents. Story

> The Design of Medical Devices Conference, promoted as the world's largest medical device conference, is scheduled from April 10 through April 12 at the University Hotel Minneapolis. Blog

> CT scans better identify aggressive lung cancers when they're the most treatable compared with traditional lung cancer detection methods, a new study from the Mount Sinai School of Medicine concludes. Release

> Smiths Medical is voluntarily pulling its CoZmonitor Blood Glucose Monitoring Systems from the Canadian market, because test strips used with the monitor are no longer available and the company doesn't have a compatible alternative. Release

And Finally... CBS' "Sunday Morning" program follows the story of Dr. Robert Hauser, of Abbott Northwestern Hospital's Minneapolis Heart Institute, who has pushed for more regulatory safety for device implants after the loss of a young patient whose cardiac defibrillator malfunctioned. Story

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.